Hematological Toxicity of Immune Checkpoint Inhibitors: Real-World Retrospective Outcomes from a Cohort Study in Qatar

被引：1
|
作者：
Benkhadra, Maria [1 ]
Elazzazy, Shereen [1 ]
Hamad, Anas Ahmad [1 ]
Elkhatim, Mohamed S. [2 ]
Gulied, Amaal [1 ]
Sahal, Arwa Osama [1 ]
Alasmar, Aya [1 ]
Jibril, Farah I. [1 ]
Afifi, Hebatalla Mahmoud [1 ]
Nasser, Sahar [1 ]
Alnajjar, Afnan [1 ]
Dawoud, Rawan [1 ]
Omar, Nabil E. [1 ,3 ]
机构：
[1] Hamad Med Corp, Dept Pharm, Natl Ctr Canc Care & Res, Doha, Qatar
[2] Hamad Med Corp, Dept Med Oncol, Natl Ctr Canc Care & Res, Doha, Qatar
[3] Qatar Univ, Coll Pharm, Clin & Populat Hlth Res, Doha, Qatar
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-180648
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [11] Real-world data in the era of immune checkpoint inhibitors
    Narita, Yukiya
    ANNALS OF ONCOLOGY, 2021, 32 : S250 - S250
  • [12] Myositis with immune checkpoint inhibitors in a real-world setting
    Reactions Weekly, 2020, 1794 (1) : 11 - 11
  • [13] Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study
    Assie, Jean-Baptiste
    Crepin, Florian
    Grolleau, Emmanuel
    Canellas, Anthony
    Geier, Margaux
    Grebert-Manuardi, Aude
    Akkache, Nabila
    Renault, Aldo
    Hauss, Pierre-Alexandre
    Sabatini, Marielle
    Bonnefoy, Valentine
    Cortot, Alexis
    Wislez, Marie
    Gauvain, Clement
    Chouaid, Christos
    Scherpereel, Arnaud
    Monnet, Isabelle
    CANCERS, 2022, 14 (06)
  • [14] Hyperprogression on immune checkpoint inhibitors: A single institution, real-world retrospective analysis.
    Paydary, Koosha
    Moturi, Krishna Rekha
    Baral, Binav
    Farooq, Muhammad Zain
    Lad, Thomas E.
    Mangla, Ankit
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [15] Comparison of clinical safety between standard versus extended interval dosing of immune checkpoint inhibitors: a real-world retrospective cohort study
    Colard-Thomas, J.
    Manceron, C.
    Duflos, C.
    Herman, F.
    Simon, M.
    Maria, A. T. J.
    Faillie, J. -L.
    Viala, M.
    Palassin, P.
    ESMO OPEN, 2023, 8 (06)
  • [16] The real-world treatment characteristic and efficacy of immune checkpoint inhibitors in non-small cell lung cancer: Data from a retrospective cohort study
    Zhang, Chenyang
    Shao, Jun
    Tang, Xiaolong
    Wu, Jiayang
    Li, Peiyi
    Li, Weimin
    Wang, Chengdi
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 134
  • [17] Real-world incidences and risk factors of immune-related adverse events in patients treated with immune checkpoint inhibitors: A nationwide retrospective cohort study
    Kim, Yong Joon
    Lee, Myeongjee
    Kim, Eun Hwa
    Lee, Seulkee
    Park, Sejung
    Shin, Sang Joon
    Jung, Inkyung
    Lee, Choong-kun
    CANCER LETTERS, 2024, 596
  • [18] Real-World Outcomes for Patients Treated With Immune Checkpoint Inhibitors in the Veterans Affairs System
    La, Jennifer
    Cheng, David
    Brophy, Mary T.
    Do, Nhan V.
    Lee, Jerry S. H.
    Tuck, David
    Fillmore, Nathanael R.
    JCO CLINICAL CANCER INFORMATICS, 2020, 4 : 918 - 928
  • [19] Retreatment with immune checkpoint inhibitors (ICIs) for patients with advanced gastric cancer: A retrospective, real-world study.
    Jia, Yong-Xu
    Liu, Yihan
    Han, Hui-Qiong
    Gao, Ya-Ping
    Qin, Yanru
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 343 - 343
  • [20] A real-world data of Immune checkpoint inhibitors in solid tumors from India
    Noronha, Vanita
    Abraham, George
    Patil, Vijay
    Joshi, Amit
    Menon, Nandini
    Mahajan, Abhishek
    Janu, Amit
    Jain, Srushti
    Talreja, Vikas T.
    Kapoor, Akhil
    Singh, Gunjesh Kumar
    Khaddar, Satvik
    Gupta, Kushal
    Rathinasamy, Narmadha
    Srinivas, Sujay
    Agrawal, Amit
    Ventrapati, Pradeep
    Prabhash, Kumar
    CANCER MEDICINE, 2021, 10 (05): : 1525 - 1534
12345